A "Calibrated Approach": Pharmaceutical FDI and the Evolution of Indian Patent Law

Linton, Katherine Connor; Corrado, Nicholas
August 2008
Journal of International Commerce & Economics;Aug2008, Vol. I, p163
Trade Publication
India has charted its own intellectual property (IP) path over the last 35 years, attempting to foster the growth of a domestic pharmaceutical industry and access to medicine while, more recently, also addressing the requirements of the international IP regime. Multinational companies (MNCs) have responded to India's movement towards compliance with the WTO intellectual property agreement, TRIPS, by increasing the quantity and quality of foreign direct investment (FDI) in the areas of pharmaceutical research and development (R&D) and manufacturing. By contrast, MNCs have adopted a more cautious attitude toward the patenting and commercialization of new pharmaceutical products in India, waiting to see how Indian courts and patent offices interpret the new laws, and awaiting the enactment of longdebated data protection legislation. The ultimate success of the Indian "calibrated approach" to fostering the domestic industry and access to medicine while also addressing international IP requirements remains to be seen.


Related Articles

  • Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity. Morag-Sela, Tamar; Cohn, Ilan; Kowalski, Thomas J.; Jarecki-Black, Judy; Clyde-Watson, Zoe // Nature Biotechnology;Dec2004, Vol. 22 Issue 12, p1591 

    The article discusses issues related to intellectual property (IP) rights to pharmaceuticals in Israel. The country has a very strong generic pharmaceutical industry. Israel's past record of defending and respecting IP rights has led major companies around the world to file patent applications...

  • IP: Time for a Reset? Looney, William // Pharmaceutical Executive;Apr2012, Vol. 32 Issue 4, p12 

    The article focuses on challenges facing pharmaceutical patenters with market uncertainty due to decline in patent filings, conflicting legislation for defining patentability and stalled progress on consensus to extend minimum levels of intellectual property (IP) protection. It reflects that...

  • Patent Strategies in the European Union for the Pharmaceutical Industry. Cohen, Larry; Uphoff, Boris // Venulex Legal Summaries;2003 Q1, p1 

    The article discusses the need for a community patent in the pharmaceutical industry in the European Union. The advantages of a community patent are cited. The cost of obtaining the patent is reported. The reason behind a strong political pressure for the implementation of a community patent is...

  • Intellectual Property Laws. Stuart, Michael // Pharmaceutical Technology;Jul2006, Vol. 30 Issue 7, p94 

    The article discusses the author's insights which pertain to intellectual property laws to be applied for the protection of pharmaceutical companies from competitive challenges. Pharmaceutical companies understand the benefits and boundaries of intellectual property as their valuable group of...

  • International patent systems strength 1998–2011. Papageorgiadis, Nikolaos; Cross, Adam R.; Alexiou, Constantinos // Journal of World Business;Oct2014, Vol. 49 Issue 4, p586 

    In this paper we report on a composite index of international patent systems strength for 48 developing and industrialized countries annually from 1998 to 2011. Building upon earlier indices we develop a conceptual framework informed by transaction cost theory and derive measures which emphasize...

  • Protecting Patents?  // Pharmaceutical Executive;Jan2008, Vol. 28 Issue 1, p30 

    The article focuses on the issues concerning the patent-reform legislation regarding pharmaceutical products in the U.S. According to the author, the main issue evolves in a postgrant review system that allows reevaluation of patents after they are awarded. As a result, pharmaceutical companies...

  • International Patents and International Harmonization. Sharer, Paul; Simpkins, Martina // BioPharm International;Sep2005, Vol. 18 Issue 9, p58 

    Reports on the role of protection of intellectual property rights in bilateral trade negotiations among biopharmaceutical companies with operations outside the U.S. and Europe. Importance of international harmonization of patent laws; Means of promoting effective and adequate protection of...

  • Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health? Oliveira, Maria Auxiliadora; Bermudez, Jorge Antonio Zepeda; Chaves, Gabriela Costa; Velásquez, Germán // Bulletin of the World Health Organization;Nov2004, Vol. 82 Issue 11, p815 

    Objective The World Trade Organization's Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement establishes minimum standards for intellectual property rights, including patent protection for pharmaceuticals; therefore, it may make it difficult for developing countries to gain...

  • Patent Challenges. J. W. // Pharmaceutical Executive;Jun2007, Vol. 27 Issue 6, p24 

    The article reports that Thailand Government and other third-world nations are challenging patents on critical therapies, a tactic that is stepping up into a serious international confrontation over intellectual property protection. Thailand has been trying to override drug patents on AIDS...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics